2026-04-13T03:56:04Zhttps://recercat.cat/oai/request

oai:recercat.cat:10230/708162025-07-05T22:29:42Zcom_2072_6col_2072_452952

00925njm 22002777a 4500 dc Zuberbier, Torsten author Ensina, Luis Felipe author Giménez Arnau, Anna Maria author Grattan, Clive author Kocatürk, Emek author Kulthanan, Kanokvalai author Kolkhir, Pavel author 2025-07-02T06:27:44Z 2025-07-02T06:27:44Z 2024 Chronic urticaria is a common and debilitating mast cell-driven skin disease presenting with itchy wheals, angio-oedema, or both. Chronic urticaria is classified as spontaneous (without definite triggers) and inducible (with definite and subtype-specific triggers; eg, cold or pressure). Current management guidelines recommend step-up administration of second-generation H1-antihistamines to four-fold the approved dose, followed by omalizumab and ciclosporin. However, in many patients, chronic urticaria does not respond to this linear approach due to heterogeneous underlying mechanisms. A personalised endotype-based approach is emerging based on the identification of autoantibodies and other drivers of urticaria pathogenesis. Over the past decade, clinical trials have presented promising options for targeted treatment of chronic urticaria with the potential for disease modification, including Bruton's tyrosine kinase inhibitors, anti-cytokine therapies, and mast cell depletion. This Therapeutics article focuses on the evidence for these novel drugs and their role in addressing an unmet need for personalised management of patients with chronic urticaria. http://hdl.handle.net/10230/70816 Urticària Chronic urticaria: unmet needs, emerging drugs, and new perspectives on personalised treatment